N-Oleoyl glycine is an endogenous lipoamino acid.^1,2 It increases triglyceride levels in 3T3-L1 adipocytes, an effect that can be reversed by SR141716 (rimonabant), and selectively induces the expression of mRNA encoding the cannabinoid 1 (CB1) receptor over mRNA encoding the CB2 receptor in the same cells when used at a concentration of 50 µM.² N-Oleoyl glycine (1 µM) potentiates glycine-induced chloride currents in Xenopus oocytes expressing α1-, α1β-, α2-, α2β-, or α3 subunit-containing glycine receptors but not those expressing α3β subunit-containing glycine receptors.³ It increases c-Fos protein levels, intracellular calcium levels, and Agouti-related protein (AgRP) secretion in mHypoE-38 hypothalamic cells, effects that can be reversed by AM251 .⁴ N-Oleoyl glycine (60 mg/kg) reduces binge-like ethanol intake in alcohol-preferring mice without affecting total fluid intake and does not affect sucrose intake in the sucrose preference test in mice.⁵ It reduces balance impairments, thermal hyperalgesia, mechanical allodynia, aggressiveness, and immobility time in the tail suspension test, indicating antidepressant-like activity, in a mouse model of traumatic brain injury when administered at a dose of 50 mg/kg.⁶